FindTrial
Sign In

Premixed Injectable MTA for Pulpotomy of Primary Teeth

Evaluation of clinical and radiographic outcome of premixed injectable MTA and conventional MTA as pulpotomy medicament in primary teeth : A split mouth randomised control trial - PIMTAP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055519
Enrollment
15
Registered
2023-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K040- Pulpitis

Interventions

Intervention1: Premixed injectable MTA which is injected into the pulp chamber: Premixed Injectable MTA contains MTA which is a routinely used pulpotomy medicament which is in the premixed Injectable

Sponsors

AISWARYA U S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with bilateral indication for pulpotomy without signs and symptoms of irreversible pulpal damage

Exclusion criteria

Exclusion criteria: Children with irreversible pulpal damage, sinus or fistula and children with systemic diseases

Design outcomes

Primary

MeasureTime frame
Injecatble form of MTA can be used as a Pulpotomy Medicament in Primary teeth. Clinical and radiographic assessment will be done.Timepoint: Over a period of 6 months and one year—

Secondary

MeasureTime frame
Clinical & radiographic outcome of the pulpotomy with premixed injectable MTA will be assessed over a follow up periodTimepoint: 12 months—

Countries

India

Contacts

Public ContactDrAIswarya U S

Yenepoya Dental College and Hospital

Sharansargod@yahoo.co.in9845120885

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026